MII IG PRO
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide PRO (v2027.0.0-ballot.1: 2027 Ballot 5) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

PRO-CTCAE

Overview

PRO-CTCAE is a measurement system developed by the US National Cancer Institute (NCI) for the patient-reported assessment of symptomatic adverse events in oncological clinical trials. Unlike classic PRO instruments, PRO-CTCAE is not a single questionnaire instance but an item library from which study- and tumour-specific questionnaires are assembled.

Key Properties

Property Description
Instrument type Item library (not a fixed questionnaire)
Items 124 items covering 78 adverse events
Attributes Frequency, severity, interference
Response scales 5-point Likert (0-4) for the three main attributes, binary (yes/no) for presence
Languages 60+ validated translations including German (NCI-authorised)
Recall period Past 7 days
License Freely available (NCI, no copyright)
SNOMED CT No dedicated code (MII-controlled terminology)

The Item Library Concept

PRO-CTCAE works as a modular item bank. Investigators select the adverse events relevant to their study and assemble a tumour-specific questionnaire from them:

124 items (item library)
  ├── Breast centre subset: 21 symptoms → 36 items
  ├── Prostate subset: 19 symptoms → ~35 items
  ├── Multiple myeloma: 19 symptoms → ~35 items
  └── Further tumour-specific subsets as required

Each adverse event has 1-3 items, depending on its configuration:

Configuration Items per AE Example
Severity only 1 Dry mouth
Frequency only 1 Diarrhoea
Interference/amount only 1 Hair loss
Frequency + severity 2 Nausea
Severity + interference 2 Fatigue
Frequency + interference 2 Urinary urgency
Frequency + severity + interference 3 Pain
Presence (yes/no) 1 Rash

Scoring: the Composite Grading Algorithm

Principle

The NCI composite grading algorithm (Basch et al., Clinical Trials 2021) condenses the 1-3 item values of an adverse event into a single composite grade (0-3), analogous to the CTCAE grades for symptomatic adverse events.

Algorithm

179 combinations of frequency, severity and interference are mapped onto grades 0-3. The algorithm was developed by 20 clinical investigators in a consensus process and validated quantitatively.

Example: an AE with frequency + severity + interference (rank 7)

F\S\I 0 1 2 3 4
F=1, S=0 0 1 1 2 2
F=1, S=1 1 1 1 2 2
F=1, S=2 1 2 2 2 3
F=2, S=2 2 2 2 3 3
F=3, S=3 2 2 3 3 3
F=4, S=4 2 2 3 3 3

Average Composite Score (ACS)

The ACS is the mean of all composite grades at a measurement point and reflects the overall adverse-event burden:

ACS = sum(composite grades) / count(scored symptoms)
  • Range: 0.0 - 3.0 (continuous)
  • Symptoms with opt-out answers are excluded (not counted as 0)

FHIR Implementation

Architecture

The PRO-CTCAE implementation uses a CQL-based scoring architecture:

QuestionnaireResponse (raw answers)
  │
  ├── Form renderer → calculatedExpression → score in the QR → $extract → Observations
  │   (client-side, for interactive forms)
  │
  └── Library/$evaluate → CQL CompositeGrade() → FastAPI ETL → Observations
      (server-side, for import/ETL pipelines)

Architectural decision (spike April 2026): HAPI FHIR CR evaluates calculatedExpression neither on $extract nor on $populate. Server-side scoring therefore goes through Library/$evaluate with a dedicated CQL library.

Resource Overview

Resource Id Description
CodeSystem mii-cs-pro-pro-ctcae 124 items, 78 AEs, EN+DE, opt-out codes
ValueSet (9×) mii-vs-pro-pro-ctcae-* Frequency, severity, interference, presence + special scales
Questionnaire mii-qst-pro-pro-ctcae-breast-de Breast centre subset (21 symptoms, DE)
ObservationDefinition mii-obsdef-pro-score-proctcae-composite-grade Composite grade (0-3)
ObservationDefinition mii-obsdef-pro-score-proctcae-acs Average composite score (0.0-3.0)
CQL library mii-lib-pro-ctcae CompositeGrade(), ACS, opt-out handling

CQL Library

The CQL library PRO_CTCAE implements the complete NCI composite grading algorithm:

// Main entry point — returns a tuple {score, absentReason}
define CompositeGradeResult:
  case
    when optOutNotApplicable then Tuple { score: null, absentReason: 'not-applicable' }
    when optOutPreferNotToAnswer then Tuple { score: null, absentReason: 'asked-declined' }
    else Tuple { score: CompositeGrade, absentReason: null }
  end

// ACS with opt-out filtering
define ACSResult:
  Tuple {
    score: Avg(compositeScores where not null),
    scoredCount: Count(compositeScores where not null),
    excludedCount: Count(compositeScores where null)
  }

dataAbsentReason on Opt-Out Answers

Some PRO-CTCAE items carry opt-out options (for example "not sexually active", "does not apply to me"). These yield no score — the resulting Observation instead carries a dataAbsentReason:

Opt-out answer FHIR dataAbsentReason Description
Does not apply to me not-applicable The question is not relevant to this patient
Not sexually active not-applicable Domain not applicable
Prefer not to answer asked-declined The patient declines to answer

Special Response Scales

Beyond the four base scales there are extended scales for specific items:

ValueSet Items Additional options
severity-radiation Radiation (#36) + "does not apply to me"
severity-sexual Erection, sexual interest, vaginal pain (#66, 68, 71) + "not sexually active" + "prefer not to answer"
frequency-sexual Ejaculation problems (#67) + "not sexually active" + "prefer not to answer"
presence-na Menstruation, injection site (#57, 58, 79) + "does not apply to me"
presence-sexual Orgasm (#69, 70) + "not sexually active" + "prefer not to answer"

Breast Centre Subset (21 symptoms)

The first implemented subset is based on the validation study by Hamacher et al. (BMC Cancer 2023) at three German outpatient cancer centres with 101 breast cancer patients.

Selected Symptoms

# Symptom AE no. Attributes Items
1 Fatigue 53 Sev + Int 2
2 Numbness/tingling 39 Sev + Int 2
3 Nausea 9 Frq + Sev 2
4 Muscle pain 50 Frq + Sev + Int 3
5 Sleep problems 52 Sev + Int 2
6 Hair loss 27 Amount 1
7 Joint pain 51 Frq + Sev + Int 3
8 Blurred vision 41 Sev + Int 2
9 Concentration problems 46 Sev + Int 2
10 Pain (general) 48 Frq + Sev + Int 3
11 Diarrhoea 16 Frq 1
12 Constipation 15 Sev 1
13 Taste changes 7 Sev 1
14 Dizziness 40 Sev + Int 2
15 Shortness of breath 19 Sev + Int 2
16 Heart palpitations 23 Frq + Sev 2
17 Memory problems 47 Sev + Int 2
18 Arm/leg swelling 22 Frq + Sev + Int 3
19 Rash 24 Presence 1
20 Nail ridging 32 Presence 1
21 Nail discolouration 33 Presence 1

Total: 36 items

References

  1. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.
  2. Basch E, Becker C, Rogak LJ, et al. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clinical Trials. 2021;18(1):104-114.
  3. Haverkamp C, et al. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Ann Oncol. 2016;27(suppl_6):vi369.
  4. Hamacher S, et al. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers. BMC Cancer. 2023;23:638.
  5. NCI PRO-CTCAE Item Library v1.0 — German. Available at: https://healthcaredelivery.cancer.gov/pro-ctcae/